Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 3Sarcoma 3Pancreatic Neoplasms 2Osteosarcoma 2Neuroendocrine Tumors 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoid Tumor 1Biliary Tract Neoplasms 1Advanced Colorectal Cancer 1

Interventions

Cisplatin 2tislelizumab 1surufatinib 1spartalizumab 1sapanisertib 1pegfilgrastim 1fosbretabulin 1efatutazone 1crolibulin 1Radiotherapy 1Paclitaxel 1Filgrastim 1Doxorubicin 1CCT239065 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Carcinoma, Anaplastic × surufatinib × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡